1 Department of Head and Neck Surgery, Liverpool Hospital , New South Wales, Sydney, Australia .
2 Department of Medicine, University of New South Wales , New South Wales, Sydney, Australia .
Thyroid. 2018 Aug;28(8):991-996. doi: 10.1089/thy.2017.0607. Epub 2018 Jul 30.
Although the importance of tumor size in papillary thyroid cancer (PTC) is well established, there is no research investigating whether age modifies the impact of tumor size, and there is conflicting evidence regarding optimal size thresholds for prognostic discrimination. We aimed to verify that tumor size is an independent prognostic factor in PTC, investigate the impact of patient age, and identify optimal size cutoffs for risk stratification using objective measures of model performance.
A retrospective analysis of 574 patients with PTC, using multivariate Cox regression models to test the impact of tumor size on recurrence-free survival (RFS). Subgroup analyses were performed in patients aged <55 and ≥55 years. Exploratory analyses to identify optimal size cutoffs for prognostic discrimination were performed using the proportion of variation explained (PVE) and Harrell's C-index.
Tumor size predicted RFS on multivariate analysis in the overall study cohort (hazard ratio [HR] 1.16; [95% confidence interval (CI)1.01-1.34]; p = 0.038). In subgroup analysis, there was no association between tumor size and RFS in patients aged <55 years (HR 1.11; [CI 0.89-1.38]; p = 0.362). In contrast, size was an independent predictor of RFS in patients aged ≥55 years (HR 1.52; [CI 1.11-2.07]; p = 0.009). In this subgroup, an optimal size threshold of >2 cm versus ≤2 cm (HR 5.24; [CI 2.30-11.92]; p < 0.001; PVE: 36%; C-index: 0.66) provided the greatest prognostic discrimination. There was no incremental improvement in prognostic value by further stratification of size.
In our PTC cohort, the impact of tumor size on RFS was limited to patients aged ≥55 years. A single size threshold of 2 cm maximized prognostic discrimination with tumors >2 cm associated with a five times higher risk of recurrence than those ≤2 cm. These findings need to be validated in independent large cohorts and the potential management and staging implications further studied.
虽然肿瘤大小在甲状腺乳头状癌(PTC)中的重要性已得到充分证实,但目前尚无研究探讨年龄是否会改变肿瘤大小的影响,并且对于用于预后区分的最佳大小阈值存在相互矛盾的证据。我们旨在验证肿瘤大小是 PTC 的独立预后因素,研究患者年龄的影响,并使用模型性能的客观指标确定风险分层的最佳大小截止值。
对 574 例 PTC 患者进行回顾性分析,使用多变量 Cox 回归模型检验肿瘤大小对无复发生存率(RFS)的影响。在年龄<55 岁和≥55 岁的患者中进行亚组分析。使用变异比例解释(PVE)和 Harrell's C 指数进行探索性分析,以确定用于预后区分的最佳大小截止值。
在整个研究队列的多变量分析中,肿瘤大小预测 RFS(危险比 [HR] 1.16;[95%置信区间(CI)1.01-1.34];p=0.038)。在亚组分析中,在年龄<55 岁的患者中,肿瘤大小与 RFS 之间无关联(HR 1.11;[CI 0.89-1.38];p=0.362)。相比之下,在年龄≥55 岁的患者中,大小是 RFS 的独立预测因素(HR 1.52;[CI 1.11-2.07];p=0.009)。在该亚组中,>2cm 与≤2cm 的最佳大小阈值(HR 5.24;[CI 2.30-11.92];p<0.001;PVE:36%;C 指数:0.66)提供了最大的预后区分。进一步对大小进行分层并没有增加预后价值的增量改善。
在我们的 PTC 队列中,肿瘤大小对 RFS 的影响仅限于年龄≥55 岁的患者。单一 2cm 大小阈值最大限度地提高了预后区分能力,与肿瘤>2cm 相比,肿瘤≤2cm 的复发风险高五倍。这些发现需要在独立的大型队列中进行验证,并进一步研究潜在的管理和分期意义。